How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) issued its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). During the same period in the previous year, the company posted ($0.22) EPS.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets () , Stifel Nicolaus () , Wunderlich () , Standpoint Research () , Duncan Williams () , Soleil Securities () , Sterne Agee CRT () , Robert W. Baird () , Wellington Shields () and Macquarie () .

NASDAQ:OTIC

Otonomy (OTIC) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free OTIC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.0085
▼
$0.0085
50-Day Range: $0.01
▼
$0.12
52-Week Range: $0.01
▼
$2.54

Volume: N/A
Average Volume: 937,525 shs
Market Capitalization: $582,479.50

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Otonomy alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Otonomy Stock (NASDAQ:OTIC)

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

Find out more here >>>

OTIC Stock News Headlines

January 23, 2023 | finance.yahoo.com

Otonomy, Inc. (OTIC) Stock Historical Prices & Data - Yahoo Finance

December 21, 2022 | finanznachrichten.de

Otonomy, Inc.: Otonomy Provides Corporate Update

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

December 19, 2022 | finance.yahoo.com

Otonomy Provides Corporate Update

November 30, 2022 | investorplace.com

5 Investors Betting Big on Otonomy (OTIC) Stock

November 29, 2022 | investorplace.com

Why Is Otonomy (OTIC) Stock Up 97% Today?

November 10, 2022 | finance.yahoo.com

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 6, 2022 | reuters.com

OTIC.OQ - Otonomy Inc | Stock Price & Latest News | Reuters

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

October 14, 2022 | marketscreener.com

OTONOMY, INC. : Results of Operations and Financial Condition (form 8-K) - Marketscreener.com

October 13, 2022 | investing.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% By Investing.com - Investing.com

October 13, 2022 | finance.yahoo.com

LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial - Yahoo Finance

October 13, 2022 | streetinsider.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 2.83% - StreetInsider.com

October 13, 2022 | benzinga.com

Otonomy shares are trading lower after the company reported higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baseline. - Otonomy (NASDAQ:OTIC) - Benzinga

October 13, 2022 | marketscreener.com

Otonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss -- Shares Nosedive - Marketscreener.com

October 13, 2022 | benzinga.com

Why Laser Photonics Shares Are Trading Higher By Around 44%, Here Are 50 Stocks Moving In Thursday’s Mid- - Benzinga

October 13, 2022 | marketscreener.com

Otonomy Sees No Clinically Meaningful Improvement With Higher Doses of OTO-413 in Patients With Hearing Loss - Marketscreener.com

October 13, 2022 | globenewswire.com

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - GlobeNewswire

October 13, 2022 | finance.yahoo.com

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss - Yahoo Finance

October 13, 2022 | finance.yahoo.com

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

October 7, 2022 | reuters.com

OTIC.O - Otonomy Inc | Stock Price & Latest News | Reuters

September 27, 2022 | marketscreener.com

APPLIED GENETIC TECHNOLOGIES CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

September 17, 2022 | marketscreener.com

OTONOMY, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com

September 9, 2022 | streetinsider.com

Form SC 13G/A OTONOMY, INC. Filed by: FEDERATED HERMES, INC. - StreetInsider.com

September 1, 2022 | finance.yahoo.com

AGTC to Participate in Upcoming Investor Conferences - Yahoo Finance

August 11, 2022 | marketscreener.com

Otonomy : Costs Associated with Exit or Disposal Activities - Form 8-K - Marketscreener.com

August 9, 2022 | marketscreener.com

OTONOMY, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K) - Marketscreener.com

See More Headlines

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OTIC
CUSIP: N/A
CIK: 1493566
Web: www.otonomy.com
Phone: (619) 323-2200
Fax: 619-291-9190
Employees: 51
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,180,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -137.86%
Return on Assets: -68.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.74
Quick Ratio: 1.74

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 4.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.97 per share
Price / Book: 0.01

Miscellaneous

Outstanding Shares: 68,527,000
Free Float: 67,780,000
Market Cap: $582,479.50
Optionable: Optionable
Beta: 1.54

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Paul E. Cayer
President, CFO, Secretary & Chief Business Officer
Anna Stepannenko
Vice President -Technical operations
Fabrice Piu
Vice President-Research & Preclinical Development
David Skarinsky
Vice President-Clinical
Jeffery J. Anderson
Vice President-Clinical Sciences

Key Competitors

View All Competitors

OTIC Stock Analysis - Frequently Asked Questions

How were Otonomy's earnings last quarter?: Otonomy, Inc. (NASDAQ:OTIC) issued its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). During the same period in the previous year, the company posted ($0.22) EPS.
What other stocks do shareholders of Otonomy own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

This page (NASDAQ:OTIC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Otonomy (OTIC) Stock Price, News & Analysis

About Otonomy Stock (NASDAQ:OTIC)

OTIC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

OTIC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info